18299-15-5

Usage

Uses

Used in Perfumery Industry:
4-Hydroxy-3-methylbenzyl alcohol is used as a fragrance ingredient in the perfumery industry for its aromatic properties. Its distinct scent is utilized to create various fragrances in perfumes, colognes, and other scented products.
Used in Disinfectants:
Due to its antibacterial properties, 4-hydroxy-3-methylbenzyl alcohol is used as a disinfectant in various applications. It helps to kill or inhibit the growth of bacteria, making it suitable for use in cleaning and sanitizing products.
Used in Pharmaceutical Industry:
4-Hydroxy-3-methylbenzyl alcohol is used in the manufacturing of pharmaceuticals. Its properties make it a valuable component in the development of drugs for various medical applications.
Used as an Antiseptic and Preservative in Cosmetic and Personal Care Products:
In the cosmetic and personal care industry, 4-hydroxy-3-methylbenzyl alcohol is used as an antiseptic and preservative. Its ability to inhibit bacterial growth helps maintain the freshness and safety of products, extending their shelf life and preventing contamination.
Used in Research for Neurological Disorders:
4-Hydroxy-3-methylbenzyl alcohol has been studied for its potential use in the treatment of certain neurological disorders. Its properties are being investigated for their possible therapeutic effects, offering a promising avenue for future medical advancements.

Upstream product

• 50-00-0 formaldehyd 
• 95-48-7 ortho-cresol 
• 15174-69-3 4-hydroxy-3-methyl-benzaldehyde 
• 56-23-5 tetrachloromethane 
• 7732-18-5 water 

Downstream Products

• 637352-50-2 ethyl [4-(hydroxymethyl)-2-methylphenoxy]acetate 
• 637352-69-3 ethyl [4-({butyl[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)-2-methylphenoxy]acetate 
• 637352-61-5 ethyl [4-({(2-cyclopropylethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)-2-methylphenoxy]acetate 
• 637352-70-6 ethyl [4-({(2-methoxyethyl)[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)-2-methylphenoxy]acetate 
• 637352-60-4 ethyl [2-methyl-4-({pentyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)phenoxy]acetate 
• 637352-58-0 ethyl [4-({butyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)-2-methylphenoxy]acetate 
• 637353-08-3 ethyl (4-{[butyl(2,4'-dimethyl-1,1'-biphenyl-3-yl)amino]methyl}-2-methylphenoxy)acetate 
• 637352-64-8 methyl [2-methyl-4-({[2-(methylthio)ethyl][4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)phenoxy]acetate 
• 637352-94-4 ethyl (4-{[(3-bromo-2-methylphenyl)(butyl)amino]methyl}-2-methylphenoxy)acetate 
• 637352-51-3 ethyl [4-(bromomethyl)-2-methylphenoxy]acetate 
• 439134-88-0 ethyl [4-(chloromethyl)-2-methylphenoxy]acetate 

Relevant academic research and scientific papers

Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents

Non-alcoholic fatty liver disease (NAFLD) has become the most common hepatic disease, while no drug was approved until now. The previous study reported that the quadruple FFA1/PPAR-α/γ/δ agonist RLA8 provided better efficacy than obeticholic acid on NASH. In the present study, two design strategies were introduced to explore better quadruple FFA1/PPAR-α/γ/δ agonists with improved metabolic stability. These efforts ultimately resulted in the identification of ZLY18, a quadruple FFA1/PPAR-α/γ/δ agonist with twice higher metabolic half-life than RLA8 in the liver microsome. In the triton-1339W-induced hyperlipidemic model, ZLY18 reversed hyperlipidemia to an almost normal level, which exhibited far stronger lipid-lowering effects than that of RLA8. Moreover, ZLY18 significantly decreased steatosis, hepatocellular ballooning, inflammation and liver fibrosis in NASH model even better than RLA8. Further mechanism studies suggested that ZLY18 exerts stronger effects than RLA8 on the regulation of the gene related to lipid synthesis, oxidative stress, inflammation and fibrosis. In addition, ZLY18 is more effective than pirfenidone in the prevention of CCl4-induced liver fibrosis. Besides, ZLY18 has an acceptable safety profile in the acute toxicity study at a high dose of 500 mg/kg. Therefore, ZLY18 represents a novel and highly promising quadruple FFA1/PPAR-α/γ/δ agonist worth of further investigation and development.

CHEMICAL COMPOUNDS

A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, .Wherein:R1 and R2 are independently hydrogen or C1-3 alkyl;X represents a bond, CH2 or O;R3 and R4 are independently hydrogen, C1-6 alkyl, OCH3, CF3, allyl or halogen;X1 is CH2, SO2, or CO;R5 is -C1-6 alkyl (optionally substituted by C1-6alkoxy or C1-6alkylthio), -C2-6 alkenyl, -C0-6 alkyl phenyl (wherein the phenyl is optionally substituted by one or more CF3, halogen, C1-3 alkyl, C1-3 alkoxy), -COC1-6 alkyl, SO2C1-6 alkyl ;R6 is phenyl or a 6 membered heteroaryl group containing 1,2 or 3 N atoms wherein the phenyl or heteroaryl group is optionally substituted with 1, 2 or 3 moieties selected from the group consisting of C1-6 alkyl, halogen, -OC1-6 alkyl, -SO2C1-3 alkyl, phenyl (optionally substituted by one or more groups selected from halogen, CF3, C1-3 alkyl, OC1-3 alkyl, acetyl, CN).